

Andrea B Apolo

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2111901/andrea-b-apolo-publications-by-year.pdf>

Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

64 papers	2,455 citations	23 h-index	49 g-index
72 ext. papers	3,342 ext. citations	6.4 avg, IF	4.85 L-index

#	Paper	IF	Citations
64	MPA software enables stitched multiplex, multidimensional EV repertoire analysis and a standard framework for reporting bead-based assays.. <i>Cell Reports Methods</i> , 2022 , 2, 100136		0
63	Cell death-induced immunogenicity enhances chemoimmunotherapeutic response by converting immune-excluded into T-cell inflamed bladder tumors.. <i>Nature Communications</i> , 2022 , 13, 1487	17.4	2
62	Evolving Role of Adjuvant Systemic Therapy for Kidney and Urothelial Cancers. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022 , 1-16	7.1	1
61	Management of adverse events associated with cabozantinib plus nivolumab in renal cell carcinoma: A review.. <i>Cancer Treatment Reviews</i> , 2021 , 103, 102333	14.4	4
60	Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2021 , 384, 829-841	59.2	280
59	Cabozantinib (C) exposure-response (ER) analysis for the phase 3 CheckMate 9ER (CM 9ER) trial of nivolumab plus cabozantinib (N+C) versus sunitinib (S) in first-line advanced renal cell carcinoma (1L aRCC).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 4561-4561	2.2	3
58	CT Evaluation of Lymph Nodes That Merge or Split during the Course of a Clinical Trial: Limitations of RECIST 1.1. <i>Radiology Imaging Cancer</i> , 2021 , 3, e200090	1.4	0
57	Clinical value of FDG PET/MRI in muscle-invasive, locally advanced, and metastatic bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021 , 39, 787.e17-787.e21	2.8	6
56	Autocrine signaling by receptor tyrosine kinases in urothelial carcinoma of the bladder. <i>PLoS ONE</i> , 2021 , 16, e0241766	3.7	2
55	Circulating Tumor Cell Subtypes and T-cell Populations as Prognostic Biomarkers to Combination Immunotherapy in Patients with Metastatic Genitourinary Cancer. <i>Clinical Cancer Research</i> , 2021 , 27, 1391-1398	12.9	7
54	Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial. <i>Lancet Oncology</i> , 2020 , 21, 1099-1109	21.7	31
53	Neurotoxicities associated with checkpoint inhibitors: Two case reports and a review of the literature. <i>Clinical Case Reports (discontinued)</i> , 2020 , 8, 24-32	0.7	5
52	Five-Factor Prognostic Model for Survival of Post-Platinum Patients with Metastatic Urothelial Carcinoma Receiving PD-L1 Inhibitors. <i>Journal of Urology</i> , 2020 , 204, 1173-1179	2.5	20
51	Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis 2020 , 8,		18
50	Systemic therapy in bladder preservation. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020 ,	2.8	1
49	Efficacy and immune-related adverse event associations in avelumab-treated patients 2020 , 8,		5
48	Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3672-3684 ^{2.2}		37

47	Ocular Adverse Events Following Use of Immune Checkpoint Inhibitors for Metastatic Malignancies. <i>Ocular Immunology and Inflammation</i> , 2020 , 28, 854-859	2.8	21
46	F-Sodium fluoride PET/CT predicts overall survival in patients with advanced genitourinary malignancies treated with cabozantinib and nivolumab with or without ipilimumab. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020 , 47, 178-184	8.8	6
45	Impact of Anatomic Location of Bone Metastases on Prognosis in Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2019 , 17, 306-314	3.3	0
44	Identification of Neoantigen-Reactive Tumor-Infiltrating Lymphocytes in Primary Bladder Cancer. <i>Journal of Immunology</i> , 2019 , 202, 3458-3467	5.3	23
43	Multi-omics Integration Analysis Robustly Predicts High-Grade Patient Survival and Identifies CPT1B Effect on Fatty Acid Metabolism in Bladder Cancer. <i>Clinical Cancer Research</i> , 2019 , 25, 3689-3701	12.9	45
42	Eligibility and Radiologic Assessment in Adjuvant Clinical Trials in Bladder Cancer. <i>JAMA Oncology</i> , 2019 , 5, 1790-1798	13.4	5
41	Quantification of bone flare on F-NaF PET/CT in metastatic castration-resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2019 , 22, 324-330	6.2	6
40	Serum Metabolic Profiling Identified a Distinct Metabolic Signature in Bladder Cancer Smokers: A Key Metabolic Enzyme Associated with Patient Survival. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019 , 28, 770-781	4	14
39	Contemporary Patterns of Multidisciplinary Care in Patients With Muscle-invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, 213-218	3.3	10
38	Clinical efficacy of cabozantinib plus nivolumab (CaboNivo) and CaboNivo plus ipilimumab (CaboNivolpi) in patients (pts) with chemotherapy-refractory metastatic urothelial carcinoma (mUC) either naïve (n) or refractory (r) to checkpoint inhibitor (CPI).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1533-1533	2.2	9
37	Results of phase I plus expansion cohorts of cabozantinib (Cabo) plus nivolumab (Nivo) and CaboNivo plus ipilimumab (Ipi) in patients (pts) with with metastatic urothelial carcinoma (mUC) and other genitourinary (GU) malignancies.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 515-515	2.2	42
36	Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. <i>Lancet Oncology</i> , 2018 , 19, 51-64	21.7	362
35	Anti-Programmed Cell Death 1/Ligand 1 (PD-1/PD-L1) Antibodies for the Treatment of Urothelial Carcinoma: State of the Art and Future Development. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, 117-129	3.3	21
34	Overview of Current and Future Adjuvant Therapy for Muscle-Invasive Urothelial Carcinoma. <i>Current Treatment Options in Oncology</i> , 2018 , 19, 36	5.4	12
33	A Phase II Clinical Trial of TRC105 (Anti-Endoglin Antibody) in Adults With Advanced/Metastatic Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, 77-85	3.3	33
32	ENABLE (Exportable Notation and Bookmark List Engine): an Interface to Manage Tumor Measurement Data from PACS to Cancer Databases. <i>Journal of Digital Imaging</i> , 2017 , 30, 275-286	5.3	6
31	Radiology Reports With Hyperlinks Improve Target Lesion Selection and Measurement Concordance in Cancer Trials. <i>American Journal of Roentgenology</i> , 2017 , 208, W31-W37	5.4	8
30	Immunotherapy: a new treatment paradigm in bladder cancer. <i>Current Opinion in Oncology</i> , 2017 , 29, 184-195	4.2	33

29	Advances in medical imaging for the diagnosis and management of common genitourinary cancers. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017 , 35, 473-491	2.8	35
28	Quantitative Assessment of Early [F]Sodium Fluoride Positron Emission Tomography/Computed Tomography Response to Treatment in Men With Metastatic Prostate Cancer to Bone. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2829-2837	2.2	39
27	Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2117-2124	2.2	415
26	Repeatability of Quantitative 18F-NaF PET: A Multicenter Study. <i>Journal of Nuclear Medicine</i> , 2016 , 57, 1872-1879	8.9	46
25	Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer. <i>Bladder Cancer</i> , 2016 , 2, 165-202		22
24	Prospective Study Evaluating Na18F PET/CT in Predicting Clinical Outcomes and Survival in Advanced Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2016 , 57, 886-92	8.9	64
23	Summary of the 8th Annual Bladder Cancer Think Tank: Collaborating to move research forward. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015 , 33, 53-64	2.8	11
22	Elevating the Horizon: Emerging Molecular and Genomic Targets in the Treatment of Advanced Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2015 , 13, 410-20	3.3	16
21	Cutaneous adverse effects associated with the tyrosine-kinase inhibitor cabozantinib. <i>JAMA Dermatology</i> , 2015 , 151, 170-7	5.1	26
20	Viable tumor volume: Volume of interest within segmented metastatic lesions, a pilot study of proposed computed tomography response criteria for urothelial cancer. <i>European Journal of Radiology</i> , 2015 , 84, 1708-14	4.7	9
19	A phase I study of TRC105 anti-endoglin (CD105) antibody in metastatic castration-resistant prostate cancer. <i>BJU International</i> , 2015 , 116, 546-55	5.6	45
18	Imaging muscle-invasive and metastatic urothelial carcinoma. <i>Current Opinion in Urology</i> , 2015 , 25, 441-82	8.8	18
17	New and promising strategies in the management of bladder cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015 , 105-12	7.1	14
16	Rapid development of migratory, linear, and serpiginous lesions in association with immunosuppression. <i>Journal of the American Academy of Dermatology</i> , 2014 , 70, 1130-4	4.5	12
15	Cabozantinib-induced thyroid dysfunction: a review of two ongoing trials for metastatic bladder cancer and sarcoma. <i>Thyroid</i> , 2014 , 24, 1223-31	6.2	22
14	Examining the management of muscle-invasive bladder cancer by medical oncologists in the United States. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 637-44	2.8	41
13	Preliminary evaluation of urinary soluble Met as a biomarker for urothelial carcinoma of the bladder. <i>Journal of Translational Medicine</i> , 2014 , 12, 199	8.5	12
12	Characterization of HGF/Met Signaling in Cell Lines Derived From Urothelial Carcinoma of the Bladder. <i>Cancers</i> , 2014 , 6, 2313-29	6.6	11

11	Targeted therapies in urothelial carcinoma. <i>Current Opinion in Oncology</i> , 2014 , 26, 305-20	4.2	31
10	Reply to D. Pouessel et al, J.B. Aragon-Ching, and B.A. Adesunloye. <i>Journal of Clinical Oncology</i> , 2014 , 32, 4172-3	2.2	
9	Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy. <i>Journal of the National Cancer Institute</i> , 2013 , 105, 499-503	9.7	63
8	Phase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancer. <i>Journal of Clinical Oncology</i> , 2013 , 31, 724-30	2.2	76
7	Targeting molecular aberrations in urothelial carcinoma: are we almost there?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013 , 195-9	7.1	3
6	Targeting Molecular Aberrations in Urothelial Carcinoma: Are We Almost There?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013 , 195-199	7.1	2
5	Practical use of perioperative chemotherapy for muscle-invasive bladder cancer: summary of session at the Society of Urologic Oncology annual meeting. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2012 , 30, 772-80	2.8	26
4	The kinetics and reproducibility of 18F-sodium fluoride for oncology using current PET camera technology. <i>Journal of Nuclear Medicine</i> , 2012 , 53, 1175-84	8.9	57
3	Clinical value of fluorine-18 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in bladder cancer. <i>Journal of Clinical Oncology</i> , 2010 , 28, 3973-8	2.2	124
2	Clinical states model for biomarkers in bladder cancer. <i>Future Oncology</i> , 2009 , 5, 977-92	3.6	10
1	Novel tracers and their development for the imaging of metastatic prostate cancer. <i>Journal of Nuclear Medicine</i> , 2008 , 49, 2031-41	8.9	109